Short Interest in Kamada Ltd. (NASDAQ:KMDA) Increases By 33.3%

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 23,200 shares, an increase of 33.3% from the December 31st total of 17,400 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average trading volume of 63,600 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Kamada in a report on Friday, January 10th.

Institutional Trading of Kamada

An institutional investor recently bought a new position in Kamada stock. Plato Investment Management Ltd bought a new position in shares of Kamada Ltd. (NASDAQ:KMDA) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 21,785 shares of the biotechnology company’s stock, valued at approximately $117,000. Institutional investors own 20.38% of the company’s stock.

Kamada Trading Down 0.4 %

NASDAQ:KMDA traded down $0.03 during mid-day trading on Thursday, hitting $6.71. The company’s stock had a trading volume of 37,540 shares, compared to its average volume of 164,636. The company has a market capitalization of $385.69 million, a price-to-earnings ratio of 23.96, a P/E/G ratio of 0.96 and a beta of 0.98. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $8.00. The stock has a fifty day moving average of $6.38 and a 200-day moving average of $5.84.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.